-The Hindustan Times A civil society group on Friday demanded key changes in the bill to protect whistleblowers, including widening its scope to bring all categories of public servants and private sector employees under its purview. The National Campaign for People's Right to Information, after day-long consultations with the families of some of the whistleblowers, asked the government to make the definition of victimisation clear in the bill. The Whistleblowers Protection Bill was...

KEY TRENDS   • According to National Sample Survey report no. 583: Persons with Disabilities in India, the percentage of persons with disability who received aid/help from Government was 21.8 percent, 1.8 percent received aid/help from organisation other than Government and another 76.4 percent did not receive aid/ help *8   • As per National Family Health Survey-4 (NFHS-4), the Under-five Mortality Rate (U5MR) was 57.2 per 1,000 live births (for the non-STs it was 38.5)...

-The Times of India It is universally recognised that for ensuring people's participation in governance and holistic development, the best instrumentality is local government. So when Parliament passed the 73rd Constitution Amendment Bill on December 23, 1992 to enshrine the essential features of panchayats in the Constitution, this was hailed as historic. But where do our panchayats stand 20 years after becoming institutions of self-government? A big issue before the founders of...

-The Hindu   It joins hands with AIIMS to offer health services to villagers Raipur: Maoists as well as security forces have hit upon new strategies to gain an upper hand in the ongoing conflict. The latest one - to check the influence of rebels - has come from the Central Reserve Police Force (CRPF). It is not at all a military manoeuvre, but an offer of medical assistance to villagers in the Maoist-controlled...

-The Economic Times WASHINGTON: Big Pharma found little support from the small guy on the street as the Indian Supreme Court's decision to reject patent claims of the drug maker Novartis for its celebrated cancer medicine Glivec reverberated across the world. The pharma lobby railed against the decision but the overwhelming sentiment, from physicians to politicians, from academia to media, particularly in a country groaning from the high cost of health care,...